Oxa-noribogaine
Pharmaceutical compound
From Wikipedia, the free encyclopedia
Oxa-noribogaine is an atypical κ-opioid receptor agonist of the "oxa-iboga" family and a synthetic benzofuran analogue of noribogaine.[1][2][3] Although it still binds to hERG with similar avidity as noribogaine, it appears to be devoid of the proarrhythmic side effects of noribogaine.[1][3]
| |
| Clinical data | |
|---|---|
| Other names | Oxanoribogaine; Oxa-noriboga; 16-Oxanoribogaine; Furanyl-noribogaine; 12-Hydroxy-16-oxaibogamine; 16-Oxaibogamin-12-ol |
| Drug class | Atypical κ-opioid receptor partial agonist |
| Identifiers | |
| |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C19H23NO2 |
| Molar mass | 297.398 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Pharmacology
Pharmacodynamics
Oxa-noribogaine acts as an atypical κ-opioid receptor (KOR) partial agonist similarly to noribogaine but shows dramatically increased potency and selectivity compared to noribogaine (EC50 = 43 nM vs. 6,100 nM, respectively; 142-fold difference).[3] It produces analgesic effects in animals, but unlike conventional KOR agonists, does not produce aversive or pro-depressive effects.[1][3] The drug induces a robust KOR-dependent increase in GDNF levels in the ventral tegmental area (VTA) and medial prefrontal cortex (mPFC).[1][3] After a single dose or short-term treatment, oxa-noribogaine induces long-lasting suppression of opioid drug-seeking behavior in rodent relapse models.[1][3] It also counteracts persistent opioid-induced hyperalgesia.[3] In addition, oxa-noribogaine decreases alcohol consumption in rodents.[4]